Table 3 Risk factors for eradication failure in univariate analysis
| Â | Triple therapy with clarithromycin | Triple therapy with levofloxacin | ||||
|---|---|---|---|---|---|---|
|  | Failure (n = 32) | Success (n = 71) | P/OR (95% CI) | Failure (n = 24) | Success (n = 27) | OR (95% CI);P |
Female | 27 (84.4%) | 46 (64.8%) | 0.043/2.94 (1.01–8.57) | 19 (79.2%) | 20 (74.1%) | 0.749 |
Age | 41.5 ± 13.7 | 41.7 ± 12.6 | 0.967 | 45.2 ± 10.4 | 45.3 ± 16.6 | 0.678 |
>50Â years | 9 (28.1%) | 22 (31%) | 0.820 | 9 (37.5%) | 10 (37%) | 1 |
Caucasian | 30 (93.8%) | 69 (97.2%) | 0.586 | 23 (95.8%) | 27 (100%) | 0.471 |
No education or primary school | 20 (62.5%) | 53 (74.6%) | 0.245 | 8 (33.3%) | 11 (40.7%) | 0.772 |
Urban residence | 11 (34.4%) | 37 (52.1%) | 0.135 | 12 (50%) | 9 (33.3%) | 0.265 |
Non-ulcer dyspepsia | 22 (68.8%) | 41 (57.7%) | 0.383 | 13 (54.2%) | 21 (77.8%) | 0.136 |
GERD/Chronic therapy with PPI | 6 (18.8%) | 18 (25.4%) | 0.616 | 9 (37.5%) | 8 (29.6%) | 0.569 |
First-degree relatives with gastric cancer | 5 (15.6%) | 9 (12.7%) | 0.759 | 3 (12.5%) | 4 (14.8%) | 1 |
Iron-deficient anemia | 6 (18.8%) | 19 (26.8%) | 0.462 | 4 (16.7%) | 3 (11.1%) | 0.693 |
Peptic ulcer | 1 (3.1%) | 8 (11.3%) | 0.268 | 3 (12.5%) | 1 (3.7%) | 0.331 |
BMI | 23.3 ± 3.3 | 25.2 ± 4.4 | 0.035 | 26.2 ± 4.4 | 23.9 ± 3.3 | 0.064 |
BMI < 26 kg/m2 | 29 (90.6%) | 44 (62%) | 0.004/5.92 (1.65–21.28) | 13 (54.2%) | 21 (77.8%) | 0.136 |
Smoking | 7 (21.9%) | 6 (8.5%) | 0.104 | 6 (25%) | 5 (18.5%) | 0.736 |
Alcohol consumption | 4 (12.5%) | 17 (23.9%) | 0.290 | 3 (12.5%) | 7 (25.9%) | 0.300 |
Olive oil consumption ≥1 dl/week | 18 (56.2%) | 35 (49.3%) | 0.531 | 11 (45.8%) | 16 (59.3%) | 0.406 |
History of frequent infections | 11 (34.4%) | 9 (12.7%) | 0.015/3.61 (1.31–9.91) | 7 (29.2%) | 6 (22.2%) | 0.749 |
Antibiotic consumption in the last 12Â months | 12 (37.5%) | 16 (22.5%) | 0.151 | 19 (79.2%) | 21 (77.8%) | 1 |
Family history of gastric diseases | 18 (56.2%) | 31 (43.7%) | 0.289 | 11 (45.8%) | 18 (66.7%) | 0.164 |
Adverse events | 13 (40.6%) | 32 (45.1%) | 0.830 | 8 (33.3%) | 8 (29.6%) | 1 |
Incomplete treatment | 6 (18.8%) | 19 (26.8%) | 0.462 | 3 (12.5%) | 0 (0%) | 0.097 |
No compliance | 2 (6.2%) | 5 (7%) | 1 | 2 (8.3%) | 0 (0%) | 0.216 |
CagA negative | 24 (75%) | 35 (49.3%) | 0.018/3.09 (1.22–7.81) | 20 (83.3%) | 21 (77.8%) | 0.731 |
vacA s1m1 | 3 (9.4%) | 21 (29.6%) | 0.026/0.25 (0.07–0.90) | 3 (12.5%) | 1 (3.7%) | 0.331 |
vacA s1m2 | 7 (21.9%) | 21 (29.6%) | 0,480 | 5 (20.8%) | 7 (25.9%) | 0.749 |
vacA s2m1 | 0 (0%) | 1 (1.4%) | 1 | 0 (0%) | 2 (7.4%) | 0.492 |
vacA s2m2 | 22 (68.8%) | 28 (39.4%) | 0.01/3.38 (1.39–8.20) | 16 (66.7%) | 17 (63%) | 1 |